Abuses of FDA Regulatory Procedures

The Case of Suboxone

Published in: New England Journal of Medicine, Volume 382, Number 6, pages 496–498 (February 2020). doi: 10.1056/NEJMp1906680

Posted on RAND.org on April 29, 2020

by Rebecca Lee Haffajee, Richard G. Frank

Read More

Access further information on this document at New England Journal of Medicine

This article was published outside of RAND. The full text of the article can be found at the link above.

Only about 20% of the more than 2 million Americans with an opioid use disorder (OUD) receive treatment in a given year, much of which is not evidence-based. Buprenorphine, one of several medications used to treat OUD, substantially reduces the risk of overdose and can be delivered in office-based settings. Various barriers impede widespread access to buprenorphine, however, including federal requirements that clinicians obtain a waiver to prescribe it. In addition, high prices for brand-name buprenorphine formulations strain the budgets of public programs, which cover a disproportionately large share of people with OUD. In 2017, Medicare and Medicaid were responsible for 32% of the $2.58 billion in prescription buprenorphine sales. The bulk of these sales was for Suboxone, a patent-protected buprenorphine–naloxone sublingual film made by Reckitt Benckiser Pharmaceuticals (now separated from its former parent company and known as Indivior).

Research conducted by

This report is part of the RAND Corporation external publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.